Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation

Abstract

Objectives: Mycophenolic acid (MPA) is an immunosuppressive agent which is commonly used in a fixed dose regime in solid organ transplantation. For clinical trials and therapeutic drug monitoring measuring plasma concentrations is necessary. Also, stability issues have to be addressed.Methods: We describe an isocratic, RP-based HPLC-UV method for simultaneous determination of MPA and its major metabolite Mycophenolic acid 7-o Glucuronide (MPAG) in human plasma. Pre-analytics included protein precipitation with acetonitrile. The method was validated according to EMA/FDA guidelines. Patient lithium-heparin plasma and blood was used for evaluation of short-term (72 hours at room temperature = RT) and long-term stability (2 years at −80 °C) without acidification.Results: Linearity was assessed in the concentration range of 0.5–40.0 μg/mL for MPA and 5.0–350.0 μg/mL for MPAG, respectively. For MPA coefficient of variation was <7.0% (lower limit of quantification = LLOQ: 10.8%), for MPAG <9.6% (LLOQ: 10.6%). Bias ranged between −1.9 and +1.5% for MPA and for MPAG between −4.3 and −0.3%. The method showed agreement with a reference method for both analytes. MPA remained stable for 7 h (−1.6 to +8.4% change to the initial concentration) and MPAG for 24 h (−1.8 to −11.5% change) at RT in lithium heparin blood. After 2 years of storage at −80 °C MPA, MPAG concentrations and 95% CIs remained within ±15% of the initial value.Conclusion: The presented assay is applicable for clinical studies. Blood samples were stable for 7 hours at RT and plasma for 2 years stored at −80 °C.